Protocol Review and Monitoring System ABSTRACT The City of Hope Comprehensive Cancer Center (COHCCC) has a well-established system for review, oversight, and support of cancer research conducted by its investigators. The system includes review by (1) Multidisciplinary Disease and Modality Teams for City of Hope (COH) investigator initiated concepts; (2) the Cancer Protocol Review and Monitoring Committee (CPRMC); (3) the Data Safety Monitoring Committee (DSMC); and (4) the COH designated Institutional Review Boards. The offices that support these committees are centralized within COH?s Research Protections Unit and respectively include the Protocol Scientific Review and Monitoring Office (PSRMO), the Data and Safety Monitoring Office (DSMO); and the Office for Human Research Subject Protections (OHRSP). The COHCCC Protocol Review and Monitoring System (PRMS) is focused on the scientific merit of protocols, prioritization and feasibility of trial completions, as well as oversight of the progress of approved research and termination of research that no longer meets criteria for ongoing continuation. The PRMS is overseen by the CPRMC, which coordinates with investigators and multidisciplinary Disease and/or Modality Teams. The CPRMC is administratively supported by the PSRMO. All proposed cancer research must be reviewed and approved by the CPRMC either through a convened review process or through expedited administrative scientific review for prioritization, as permitted by the CCSG for peer-reviewed research, and reviewed for scientific progress on at least an annual basis. The CPRMC has authority to close trials that do not demonstrate scientific progress, and all appeals are evaluated by the CPRMC. The PRMS continues under the leadership of Karen Reckamp, MS, MD, who has chaired the CPRMC since 2012. Dr. Reckamp is appointed by and reports directly to the Cancer Center Director. The PSRMO is under the direction of Amanda Hammond, JD, Sr. Director of the Research Protections Unit who reports to Ashley Baker Lee, COH?s Senior Vice President for Research Operations. The PRMS was conditionally approved in 2012 and received full approval in 2014.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059216
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Mendez-Dorantes, Carlos; Bhargava, Ragini; Stark, Jeremy M (2018) Repeat-mediated deletions can be induced by a chromosomal break far from a repeat, but multiple pathways suppress such rearrangements. Genes Dev 32:524-536
Bzymek, Krzysztof P; Puckett, James W; Zer, Cindy et al. (2018) Mechanically interlocked functionalization of monoclonal antibodies. Nat Commun 9:1580
Nguyen, Huong Q; Ruel, Nora; Macias, Mayra et al. (2018) Translation and Evaluation of a Lung Cancer, Palliative Care Intervention for Community Practice. J Pain Symptom Manage 56:709-718
Satheesan, Sangeetha; Li, Haitang; Burnett, John C et al. (2018) HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy. J Virol 92:
Zhang, Jing; He, Zhiheng; Sen, Subha et al. (2018) TCF-1 Inhibits IL-17 Gene Expression To Restrain Th17 Immunity in a Stage-Specific Manner. J Immunol 200:3397-3406
Sun, Jie; He, Xin; Zhu, Yinghui et al. (2018) SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. Cell Stem Cell 23:355-369.e9
Miao, Yifei; Ajami, Nassim E; Huang, Tse-Shun et al. (2018) Enhancer-associated long non-coding RNA LEENE regulates endothelial nitric oxide synthase and endothelial function. Nat Commun 9:292
Sen, Subha; Wang, Fei; Zhang, Jing et al. (2018) SRC1 promotes Th17 differentiation by overriding Foxp3 suppression to stimulate ROR?t activity in a PKC-?-dependent manner. Proc Natl Acad Sci U S A 115:E458-E467
Murad, John P; Kozlowska, Anna K; Lee, Hee Jun et al. (2018) Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Front Immunol 9:2268
Brown, Christine E; Aguilar, Brenda; Starr, Renate et al. (2018) Optimization of IL13R?2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Mol Ther 26:31-44

Showing the most recent 10 out of 1396 publications